Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent
neurodegenerative diseases, affecting millions and costing billions each year in the United …

Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …

Alzheimer's disease (AD) and other dementias represent a significant and increasing clinical
challenge. This review highlights current treatment options for AD and the main focusses of …

Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

Nanotechnology employs engineered materials or devices that interact with biological
systems at a molecular level and could revolutionize the treatment of neurodegenerative …

Due to limitations posed by the restrictive blood–brain barrier, conventional drug delivery
systems do not provide adequate cyto‐architecture restoration and connection patterns that …

Alzheimer's disease (AD) is an age-associated neurodegenerative disease that is reaching
epidemic proportions as a result of the aging of the world's population. Impressive gains in …

Introduction: Alzheimer's disease (AD) is a daunting public health threat that has prompted
the scientific community's ongoing efforts to decipher the underlying disease mechanism …

Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of
patients worldwide and costing billions of dollars annually. We review the pipeline of drugs …

Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive
research. Nowadays, only symptomatic treatments exist for this disease, all trying to …